Are You a Candidate for Stem Cell Therapy? An Honest Assessment Guide

Why candidacy is the whole ballgame

Across every application discussed on this blog, one factor predicts outcomes more reliably than cell source, cell count, clinic reputation or price: whether the patient was a genuine candidate in the first place. A technically excellent treatment delivered to someone whose condition it cannot help produces a disappointing result, and the disappointment is usually blamed on the therapy rather than on the selection.

This is why the assessment matters so much, and why a clinic's willingness to decline patients is one of the strongest signals of its integrity. A provider who finds that essentially everyone who inquires is a suitable candidate is not running an assessment process; they are running a sales process with a medical vocabulary.

The purpose of this article is to let you assess yourself honestly before anyone else does, using the same framework a responsible physician would apply. Some readers will finish it recognizing they are a reasonable candidate for a specific, targeted use. Others will recognize that the honest answer for their situation is not yet, or not at all — and knowing that before spending money is genuinely valuable.

The absolute exclusions

Some circumstances make cell therapy inadvisable regardless of the target condition, and a clinic that does not screen for them is not practicing medicine responsibly.

Active cancer is the most important. The concern is theoretical rather than proven, but it is taken seriously: cell therapies involve growth-promoting and immunomodulatory signaling, and administering them in the presence of active malignancy is not something responsible clinicians do. A history of cancer in remission requires individual assessment and oncological input rather than a blanket yes or no. Active infection, whether systemic or local at the intended treatment site, must be resolved first.

Other standard exclusions include pregnancy and breastfeeding, since safety has not been established; certain blood disorders and clotting abnormalities, which affect both the procedure and any harvest; and some immune disorders or immunosuppressive regimens, which require specialist judgment rather than a clinic's general policy. Uncontrolled serious medical conditions — poorly controlled diabetes, unstable cardiac disease — generally need stabilizing first. Any of these findings should prompt a conversation, not a workaround.

The stage question: is there anything left to work with?

This is where most candidacy decisions are actually made, and it is the point patients most often misunderstand. Biologic therapies work by influencing a biological environment. That means they need a biological environment that still exists.

In joints, this translates directly. Mild to moderate osteoarthritis with cartilage remaining is where intra-articular cell therapy has its most plausible role. End-stage, bone-on-bone arthritis is not something an injection reverses, and for that situation joint replacement is the established answer, as our comparison of the two explains in detail.

The same logic applies elsewhere. A partial-thickness rotator cuff tear or a degenerative tendinopathy is a reasonable target; a full-thickness retracted tear is a mechanical problem requiring surgical repair, covered in our shoulder article. A moderately degenerated disc with preserved height may be considered; a fully collapsed disc is not. In every case the question is the same: is there enough viable tissue for a biologic to plausibly influence? If the honest answer is no, a different treatment is indicated.

Have you actually done the conservative care?

This question disqualifies more prospective patients than any biological factor, and it disqualifies them temporarily rather than permanently. Conservative care is not a formality to be checked off before the real treatment — for many conditions it is the treatment with the best evidence.

For tendinopathy, progressive loading exercise has stronger evidence than any injection, as our tendon article sets out. For knee osteoarthritis, structured strengthening, weight management and activity modification produce real benefit. For back pain, a genuine course of physiotherapy resolves a great many cases. For plantar fasciitis, the majority resolves with stretching, strengthening and appropriate footwear.

The word "genuine" is doing important work here. A photocopied exercise sheet followed inconsistently for three weeks is not a course of physiotherapy. Three months of supervised, progressive work is. If you have not done the second, then a cell therapy is being considered as a substitute for something cheaper, safer and better-evidenced that you have not yet tried — and a physician who points this out is giving you better value than one who books you in.

Where the honest answer is that it is investigational

A separate category of candidacy question applies to conditions where cell therapy is not established at all. Across this blog we describe applications in multiple sclerosis, stroke, chronic lung disease, type 2 diabetes and others as investigational, because that is what the evidence supports.

For these, candidacy is not really a medical screening question — it is an informed-consent question. Are you being told plainly that the treatment is unproven for your condition? Is your own specialist involved? Are you continuing every established therapy? Are you spending money you can afford to lose on something that may not help? An adult who answers yes to all of these and proceeds knowingly is making a legitimate choice. An adult who has been led to believe a treatment is established when it is not has been misled.

There are also conditions where the responsible answer is simply no. We do not offer stem cell therapy for spinal cord injury, because no proven treatment exists and the field around it is heavily exploitative. A clinic willing to name conditions it declines to treat is telling you something useful about the ones it does.

How a genuine assessment works, and what to expect

A real candidacy assessment involves reviewing your imaging and records, taking a detailed history including what treatments you have already tried and how thoroughly, a physical examination, consideration of your general health and medications, and a clear discussion of what the evidence supports for your specific condition and stage. It ends with a recommendation that may be a treatment plan, a referral, a suggestion to complete conservative care first, or a decline.

Expect to be asked about age and general health, though these matter less than people assume — tissue quality and stage matter more than a birth date. Expect questions about smoking, since it impairs healing across the board. Expect to be asked what you are hoping for, because a mismatch between hope and what the therapy can deliver is itself a candidacy issue.

At HealthBridge, our medical director Dra. Olga González leads the longevity and regenerative program, and all therapies are administered by licensed physicians under Colombian regulations following individualized assessment. We decline patients, and we think that is a feature rather than a limitation. If you want to prepare for an assessment, bring your imaging and a clear account of what treatments you have tried and for how long. Our patient journey article covers what follows if you are a candidate, and our safety guide covers how to evaluate the clinic assessing you.